Pharma Focus Asia

Pfizer Developed Elranatamab for Relapsed or Refractory Multiple Myeloma

Pfizer Inc, developed investigational elranatamab a cancer immunotherapy for the treatment of indivuduals with relapsed or refractory multiple myeloma (RRMM).

Elranatamab is bindedwith B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), present on the surface of multiple myeloma (MM) cells, and the CD3 receptor found on the surface of T-cells, bringingboth multiple myeloma (MM) cells and CD3 receptor together to activate the T-cells in order to kill myeloma cells.

BsAbs, a novel form of cancer immunotherapy directly targeting two different antigens at once. One arm binding directly to the specific antigens on cancer cells and the other arm binding to T-cells, allowing both the cells types together.

MM is a blood cancer devloped in the bone marrow affecting plasma cells. Healthy plasma cells build antibodies to fight body aginst infection.

In U.S, each year 34,000 new cases of MM are diagnosed. Multiple Myeloma remains uncurable inspite of having treatment advancements and the overall survival rate of patients with multiple myeloma is over five years, and most of the patients receive four or more lines of therapy.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024